Weight gain after starting integrase inhibitor-based antiretroviral treatment occurs to a similar extent in Asian adults with HIV compared to previously studied populations in North America and southern Africa, researchers from the TREAT Asia cohort report in HIV Medicine.
Clinical trials carried out in North America, Europe and South Africa have shown a consistent pattern of greater weight gain after starting treatment in people who receive integrase inhibitor-based treatment. For example, a pooled analysis of eight large clinical trials carried out between 2003 and 2015 found that although the average weight gain two years after starting treatment was 2kg, people taking integrase inhibitors gained 3.2 kg and people taking bictegravir or dolutegravir gained just over 4kg.
Read the full story at Aidsmap.
Source : Aidsmap
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.